Prime Medicine, Inc. (NASDAQ:PRME) Stock Has Average Target Price of $7.47 According to Analysts

Posted by Stanley Muller on Sep 27th, 2026

Shares of Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) have been given an average rating of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.47.

A number of brokerages recently issued reports on PRME. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st. TD Cowen reaffirmed a “buy” rating on shares of Prime Medicine in a report on Wednesday, July 8th. New Street Research set a $8.00 price target on shares of Prime Medicine in a research report on Monday, June 29th. Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Prime Medicine in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Prime Medicine in a research note on Monday, August 10th.

Check Out Our Latest Stock Analysis on PRME

Prime Medicine Stock Performance

NASDAQ PRME opened at $2.90 on Tuesday. The business’s fifty day moving average is $3.24 and its 200 day moving average is $3.37. Prime Medicine has a fifty-two week low of $2.67 and a fifty-two week high of $6.94. The company has a market capitalization of $526.00 million, a PE ratio of -2.74 and a beta of 2.34.

Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.24) EPS for the quarter, hitting analysts’ consensus estimates of ($0.24). Prime Medicine had a negative return on equity of 188.27% and a negative net margin of 4,613.11%.The business had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $4.40 million. On average, sell-side analysts forecast that Prime Medicine will post -0.96 EPS for the current year.

Institutional Trading of Prime Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System raised its position in shares of Prime Medicine by 15.5% during the second quarter. Arizona State Retirement System now owns 28,646 shares of the company’s stock valued at $106,000 after buying an additional 3,855 shares during the last quarter. Syon Capital LLC purchased a new stake in Prime Medicine in the 2nd quarter worth $41,000. Concurrent Investment Advisors LLC boosted its holdings in shares of Prime Medicine by 77.6% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 131,722 shares of the company’s stock valued at $486,000 after purchasing an additional 57,545 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Prime Medicine during the second quarter valued at about $1,123,000. Finally, Kingsview Wealth Management LLC purchased a new position in shares of Prime Medicine during the second quarter valued at about $37,000. Institutional investors own 70.37% of the company’s stock.

About Prime Medicine

(Get Free Report)

Prime Medicine, Inc is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient.